Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
Zhuo‐Xun Wu(St. John's University), Zhe‐Sheng Chen(St. John's University)
Cited by 45
Related Papers
Microbiota in health and diseases
|Signal Transduction and Targeted Therapy|2022|2.9k
The Phosphodiesterase-5 Inhibitor Vardenafil Is a Potent Inhibitor of ABCB1/P-Glycoprotein Transporter
|PLoS ONE|2011|81
Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells
|Molecules|2016|48
Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2
|Oncotarget|2014|47
Antimicrobial Peptide Reverses ABCB1-Mediated Chemotherapeutic Drug Resistance
|Frontiers in Pharmacology|2020|37